Biotechnology · Monmouth Junction, New Jersey, United States
$10.37
+0.19% (+$0.02)2026-08-25
Smart-Money SignalNeutral · 53/100— Insiders are net sellers over 90 days (-$6K, 6 sales vs 3 buys)
Revenue$3.9M
Net Income-$1.4M
EPS$-1.63
Market Cap$18.4M
Price Performance
Historical data including institutional events
Company Profile
C
Carl Spana
CEO & Executive Director
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
